Healthcare / BiotechnologyKOSDAQ
$502.00
-30.00 (-5.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-15.3B · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$58.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-67.0%
↓Gross Margin
-206.5%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-31.1%
FCF CAGR
—
FCF margin
-621.9%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.46B · net income $-29.67B · FCF $-15.28B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.46B | $2.46B | $373.8M | $1.03B | $7.52B |
| Net Income | $-29.67B | $-29.67B | $-26.27B | $-16.99B | $-37.22B |
| EBITDA | $-22.02B | $-22.02B | $-19.80B | $-9.73B | $-29.47B |
| EPS | -412.00 | -412.00 | -589.00 | -511.00 | -1461.00 |
| Gross Margin | -206.5% | -206.5% | -2095.5% | -624.2% | 63.1% |
| Operating Margin | -420.6% | -420.6% | -5275.4% | -1643.8% | -309.5% |
| Net Margin | -1207.7% | -1207.7% | -7027.0% | -1649.4% | -494.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.85 | 0.59 | -0.92 |
| Current Ratio | 1.49 | 1.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.28B | $-15.28B | $-13.46B | $-18.03B | $-15.49B |
| Returns | |||||
| ROE | -67.0% | -67.0% | -128.3% | -47.0% | 138.7% |
| Valuation | |||||
| P/B | 0.82 | 0.82 | 1.31 | 2.03 | — |
| Growth & Yield | |||||
| Revenue Growth | 557.3% | 557.3% | -63.7% | -86.3% | — |
| EPS Growth | 30.1% | 30.1% | -15.3% | 65.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-589.00 → -412.00
Residual
-65.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.